Foxo Technologies enters agreement to acquire Vector Biosource

FOXO Technologies (FOXO) signed a stock purchase agreement to acquire Vector Biosource. Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 and is expected to grow significantly post-acquisition. The expected purchase price consists of: $500,000 in cash, 60,000 shares of the Company’s Series E Cumulative Redeemable Secured Preferred Stock, warrants to purchase $2M of the Company’s common stock at a 10% premium to the common stock’s closing price one day prior to closing, and up to an additional 80,000 shares of Series E Preferred Stock subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. Closing is expected to occur as soon as practical after a number of closing conditions are satisfied including, but not limited to, completion of due diligence and forms of warrant and employment agreements being finalized. In addition, FOXO has agreed to fund up to $1.2M of Vector’s growth initiatives.